After sweep of deals in 2023, Gilead to focus on 'late research, early development' pipeline
Gilead is still hunting for deals, particularly in virology, oncology and inflammation.
During Tuesday’s fourth-quarter earnings call, CEO Daniel O’Day said M&A decisions will be “driven by the science,” with a focus on building up the company’s “late research, early development pipeline.” He added that the company will consider later-stage deals “as they fit into our portfolio and our range.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.